Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionKnott David M
Latest Disclosed Ownership865,500 shares
Ownership 4.10%
Knott David M ownership in LGND / Ligand Pharmaceuticals Incorporated

2018-02-13 - Knott David M has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 865,500 shares of Ligand Pharmaceuticals Incorporated (US:LGND). This represents 4.1 percent ownership of the company. In their previous filing dated 2017-02-13 , Knott David M had reported owning 1,100,656 shares, indicating a decrease of -21.37 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2018-02-13 2018-02-13 13G/A 1,100,656 865,500 -21.37 4.10 -22.64
2017-02-13 2017-02-13 13G/A 1,302,322 1,100,656 -15.49 5.30 -14.52
2016-05-24 2016-05-24 13D/A 1,302,322 6.20
2013-09-16 2013-09-16 13D/A 1,379,312 6.70

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2021-11-12 2021-09-30 13F Ligand Pharmaceuticals Common 53220K504 75,000 0 0.00 10,449 6.20 2.9570
2021-08-13 2021-06-30 13F Ligand Pharmaceuticals Common 53220K504 75,000 0 0.00 9,839 -13.95 3.4972
2021-05-13 2021-03-31 13F Ligand Pharmaceuticals Common 53220K504 75,000 -173,041 -69.76 11,434 -53.65 4.8914
2021-02-12 2020-12-31 13F Ligand Pharmaceuticals Common 53220K504 248,041 0 0.00 24,667 4.33 11.1630
2020-11-13 2020-09-30 13F Ligand Pharmaceuticals Common 53220K504 248,041 -25,000 -9.16 23,644 -22.58 13.8722
2020-08-12 2020-06-30 13F Ligand Pharmaceuticals Common 53220K504 273,041 -80,000 -22.66 30,540 18.96 16.6716
2020-05-13 2020-03-31 13F Ligand Pharmaceuticals Common 53220K504 353,041 0 0.00 25,673 -30.27 16.2021
2020-02-14 2019-12-31 13F Ligand Pharmaceuticals Common 53220K504 353,041 0 0.00 36,819 4.78 14.9248
2019-11-12 2019-09-30 13F Ligand Pharmaceuticals Common 53220K504 353,041 0 0.00 35,141 -12.80 14.7631
2019-08-12 2019-06-30 13F Ligand Pharmaceuticals Common 53220K504 353,041 9,000 2.62 40,299 -6.82 16.9992
2019-05-13 2019-03-31 13F Ligand Pharmaceuticals Common 53220K504 344,041 0 0.00 43,250 -7.36 17.2391
2019-02-12 2018-12-31 13F Ligand Pharmaceuticals Common 53220K504 344,041 0 0.00 46,686 -50.56 21.9387
2018-11-13 2018-09-30 13F Ligand Pharmaceuticals Common 53220K504 344,041 0 0.00 94,436 32.50 30.6385
2018-08-13 2018-06-30 13F Ligand Pharmaceuticals Common 53220K504 344,041 -209,000 -37.79 71,275 -21.97 26.7197
2018-05-11 2018-03-31 13F Ligand Pharmaceuticals Common 53220K504 553,041 -209,903 -27.51 91,340 -12.57 37.6519
2018-02-13 2017-12-31 13F Ligand Pharmaceuticals Common 53220K504 762,944 -35,156 -4.40 104,470 -3.86 41.5525
2017-11-13 2017-09-30 13F Ligand Pharmaceuticals Common 53220K504 798,100 -200,000 -20.04 108,661 -10.32 46.4462
2017-08-11 2017-06-30 13F Ligand Pharmaceuticals Common 53220K504 998,100 0 0.00 121,170 14.70 50.5756
2017-05-12 2017-03-31 13F Ligand Pharmaceuticals Common 53220K504 998,100 0 0.00 105,639 4.16 50.8312
2017-02-13 2016-12-31 13F Ligand Pharmaceuticals Common 53220K504 998,100 0 0.00 101,417 -0.44 51.0395
2016-11-10 2016-09-30 13F Ligand Pharmaceuticals Common 53220K504 998,100 -201,666 -16.81 101,866 -28.81 52.5828
2016-08-12 2016-06-30 13F Ligand Pharmaceuticals Common 53220K504 1,199,766 0 0.00 143,096 11.37 32.9641
2016-05-12 2016-03-31 13F Ligand Pharmaceuticals Common 53220K504 1,199,766 0 0.00 128,483 -1.23 34.2304
2016-02-12 2015-12-31 13F Ligand Pharmaceuticals Common 53220K504 1,199,766 0 0.00 130,079 26.59 35.6515
2015-11-12 2015-09-30 13F Ligand Pharmaceuticals Common 53220K504 1,199,766 -50,000 -4.00 102,760 -18.51 29.6353
2015-08-12 2015-06-30 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 0 0.00 126,101 30.85 26.0850
2015-05-13 2015-03-31 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 0 0.00 96,369 44.92 20.7557
2015-02-13 2014-12-31 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 0 0.00 66,500 13.24 15.6770
2014-11-12 2014-09-30 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 0 0.00 58,727 -24.56 11.1729
2014-08-12 2014-06-30 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 0 0.00 77,848 -7.40 13.9562
2014-05-13 2014-03-31 13F Ligand Pharmaceuticals Common 53220K504 1,249,766 -42,800 -3.31 84,072 23.66 16.0711
2014-02-13 2013-12-31 13F Ligand Pharmaceuticals Common 53220K504 1,292,566 0 0.00 67,989 21.53 13.8699
2013-11-12 2013-09-30 13F Ligand Pharmaceuticals Common 53220K504 1,292,566 -160,000 -11.01 55,942 2.98 10.6967
2013-08-13 2013-06-30 13F Ligand Pharmaceuticals Common 53220K504 1,452,566 54,326 11.3048
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.